Author Search Results :: UTM Library Massive Scholar Tracking

1

Metformin in prediabetes: key mechanisms for the prevention of diabetes and cardiometabolic risks by A. Yu. Babenko

Published 2022-06-01

Get full text

Article

2

Efficacy of sibutramine in different types of eating behavior in obese patients by G. A. Matveev, A. Yu. Babenko

Published 2022-06-01

Get full text

Article

3

Use of sodium-glucose co-transporter-2 inhibitors from clinical trial results to practical application in Russia by D. A. Lebedev, A. Yu. Babenko

Published 2018-09-01

Get full text

Article

4

Glucagon-like peptide-1 receptor agonists, selection within the class. The rational combination of insulin glargine 100 + lixisenatide by M. V. Martjanova, A. Yu. Babenko

Published 2020-05-01

Get full text

Article

5

Fibrosis biomarkers and echocardiographic parameters in patients with type 2 diabetes depending on the degree of albuminuria by D. A. Lebedev, M. Yu. Laevskaya, A. Yu. Babenko

Published 2021-10-01

Get full text

Article

6

Problems of blood glucose self-monitoring in patients with diabetes mellitus by Yu. A. Kononova, V. B. Bregovskiy, A. Yu. Babenko

Published 2022-01-01

Get full text

Article

7

GLYCEMIC AND NON-GLYCEMIC EFFECTS OF EXENATIDE IN PATIENTS WITH DIABETES MELLITUS OF TYPE 2 (DM2) WITH MYOCARDIAL INFARCTION by A. Yu. BABENKO, V. A. ZYKOV, E. N. GRINEVA

Published 2016-12-01

Get full text

Article

8

Main results of the ADVANCE study: clinical interpretation for endocrinologists by Alsu Gafurovna Zalevskya, A Yu Babenko, A R Volkova

Published 2009-06-01

Get full text

Article

9

Biomarkers associated with atherogenesis: current status and promising areas by M. A. Magruk, A. A. Mosikyan, A. Yu. Babenko

Published 2019-12-01

Get full text

Article

10

Evaluation of factors influencing adherence to treatment with sodium-glucose cotransporter type 2 inhibitor by D. A. Lebedev, A. A. Mosikian, A. Yu. Babenko

Published 2020-10-01

Get full text

Article

11

ASSESSMENT OF SODIUM-GLUCOSE CO-TRANSPORTER INHIBITOR IN COMBINATION WITH INSULIN ON METABOLIC PARAMETERS AND RENAL MORPHOFUNCTIONAL CHANGES IN RATS WITH EXPERIMENTAL DIABETES MELL... by D. A. Lebedev, N. P. Likhonosov, Т. P. Tuchina, V. K. Bayrasheva, A. Yu. Babenko

Published 2017-11-01

Get full text

Article

12

Polymorphism of S19W of apolipoprotein A5gene in patients with type 2 diabetes mellitus - connection with metabolic parameters and triglyceride levels by S. A. Skoryukova, M. V. Kim, A. A. Bystrova, A. Yu. Babenko, E. I. Baranova, S. N. Pchelina

Published 2015-06-01

Get full text

Article

13

$Molecular biomarker profile of heart failure with mid-range and preserved ejection fraction in patients with type 2 diabetes$

Molecular biomarker profile of heart failure with mid-range and preserved ejection fraction in patients with type 2 diabetes by D. A. Lebedev, E. A. Lyasnikova, A. A. Vasilyeva, E. Yu. Vasilyeva, A. Yu. Babenko, E. V. Shlyakhto

Published 2020-11-01

Get full text

Article

14

$Impact of obesity on echocardiographic parameters and N-terminal pro-brain natriuretic peptide levels in patients with heart failure with mid-range ejection fraction: unanswered questions$

Impact of obesity on echocardiographic parameters and N-terminal pro-brain natriuretic peptide levels in patients with heart failure with mid-range ejection fraction: unanswered qu... by E. A. Lyasnikova, A. A. Kuular, A. V. Pavlovskaya, A. N. Vlasenko, A. V. Kozlenok, A. Yu. Babenko, M. Yu. Sitnikova, E. V. Shlyakhto

Published 2021-07-01

Get full text

Article

15

«SGLT2 INHIBITORS: RATIONALE FOR THE USE IN HEART FAILURE», RESOLUTION ON THE RESULTS OF THE PANEL OF EXPERTS WITH INTERNATIONAL PARTICIPATION, ALMATY by S.A. Abzaliyeva, G. A.Junusbekova, I.V. Zhirov, G.K. Zhusupova, K.B. Abzaliyev, M.K. Tundybaeva, R.B. Bazarbekova, A.M. Raisova, A.Yu. Babenko, V.A. Ionin

Published 2022-12-01

Get full text

Article

16

«SGLT2 INHIBITORS: RATIONALE FOR THE USE IN HEART FAILURE», RESOLUTION ON THE RESULTS OF THE PANEL OF EXPERTS WITH INTERNATIONAL PARTICIPATION, ALMATY by S.A. Abzaliyeva, G. A. Junusbekova, I.V. Zhirov, G.K. Zhusupova, K.B. Abzaliyev, M.K. Tundybaeva, R.B. Bazarbekova, A.M. Raisova, A.Yu. Babenko, V.A. Ionin

Published 2022-12-01

Get full text

Article

17

THE INTERIM EXPERTS’ COUNCIL RESOLUTION ON THE EMPA-REG OUTCOME TRIAL ISSUES by M. V. Shestakova, S. A. Boytsov, O. M. Drapkina, T. Yu. Demidova, H. Drexel, M. B. Antsiferov, N. A. Petunina, N. A. Chernikova, V. Yu. Kalashnikov, T. P. Bardymova, V. K. Protasov, A. Yu. Babenko, L. A. Ruyatkina, V. V. Klimontov, V. V. Salukhov, V. V. Fadeev, Yu. A. Karpov

Published 2016-05-01

Get full text

Article

18

Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian associa... by I. I. Dedov, N. G. Mokrysheva, M. V. Shestakova, T. V. Nikonova, A. Yu. Mayorov, G. R. Galstyan, M. Sh. Shamhalova, V. O. Barysheva, A. S. Ametov, M. B. Antsiferov, A. Yu. Babenko, T. P. Bardymova, F. V. Valeeva, A. A. Vachugova, E. N. Grineva, T. Yu. Demidova, T. P. Kiseleva, M. A. Kunicyna, T. N. Markova, A. M. Mkrtumyan, N. A. Petunina, L. A. Ruyatkina, V. V. Saluhov, L. A. Suplotova, E. L. Hadarceva, Yu. Sh. Halimov

Published 2022-03-01

Get full text

Article

Metformin in prediabetes: key mechanisms for the prevention of diabetes and cardiometabolic risks by A. Yu. Babenko

Efficacy of sibutramine in different types of eating behavior in obese patients by G. A. Matveev, A. Yu. Babenko

Use of sodium-glucose co-transporter-2 inhibitors from clinical trial results to practical application in Russia by D. A. Lebedev, A. Yu. Babenko

Glucagon-like peptide-1 receptor agonists, selection within the class. The rational combination of insulin glargine 100 + lixisenatide by M. V. Martjanova, A. Yu. Babenko

Fibrosis biomarkers and echocardiographic parameters in patients with type 2 diabetes depending on the degree of albuminuria by D. A. Lebedev, M. Yu. Laevskaya, A. Yu. Babenko

Problems of blood glucose self-monitoring in patients with diabetes mellitus by Yu. A. Kononova, V. B. Bregovskiy, A. Yu. Babenko

GLYCEMIC AND NON-GLYCEMIC EFFECTS OF EXENATIDE IN PATIENTS WITH DIABETES MELLITUS OF TYPE 2 (DM2) WITH MYOCARDIAL INFARCTION by A. Yu. BABENKO, V. A. ZYKOV, E. N. GRINEVA

Main results of the ADVANCE study: clinical interpretation for endocrinologists by Alsu Gafurovna Zalevskya, A Yu Babenko, A R Volkova

Biomarkers associated with atherogenesis: current status and promising areas by M. A. Magruk, A. A. Mosikyan, A. Yu. Babenko

Evaluation of factors influencing adherence to treatment with sodium-glucose cotransporter type 2 inhibitor by D. A. Lebedev, A. A. Mosikian, A. Yu. Babenko

ASSESSMENT OF SODIUM-GLUCOSE CO-TRANSPORTER INHIBITOR IN COMBINATION WITH INSULIN ON METABOLIC PARAMETERS AND RENAL MORPHOFUNCTIONAL CHANGES IN RATS WITH EXPERIMENTAL DIABETES MELL... by D. A. Lebedev, N. P. Likhonosov, Т. P. Tuchina, V. K. Bayrasheva, A. Yu. Babenko

Polymorphism of S19W of apolipoprotein A5gene in patients with type 2 diabetes mellitus - connection with metabolic parameters and triglyceride levels by S. A. Skoryukova, M. V. Kim, A. A. Bystrova, A. Yu. Babenko, E. I. Baranova, S. N. Pchelina

Molecular biomarker profile of heart failure with mid-range and preserved ejection fraction in patients with type 2 diabetes by D. A. Lebedev, E. A. Lyasnikova, A. A. Vasilyeva, E. Yu. Vasilyeva, A. Yu. Babenko, E. V. Shlyakhto

Search Tools: